Gemphire Therapeutics, a cardiovascular biotech developing therapies for the treatment of dyslipidemia, filed on Monday with the SEC to raise up to $60 million in an initial public offering.
The Northville, MI-based company was founded in 2014. It plans to list on the Nasdaq under the symbol GEMP. Gemphire Therapeutics filed confidentially on September 11, 2015. Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
